Liminatus Pharma Completes InnocsAI Acquisition, Issuing 11.19M Shares and Series A Preferred
Liminatus Pharma completed its acquisition of InnocsAI through an Amended and Restated Merger Agreement, enabling closing ahead of stockholder approval by using Series A Non-Voting Convertible Preferred Stock for a portion of the consideration. At closing on July 2, 2026, the company issued 11,188…